On May 26, 2021 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, reported for the first quarter 2021 (Press release, Oncopeptides, MAY 26, 2021, View Source [SID1234580656]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Oncopeptides now stands proudly among the few companies that have successfully navigated the long and difficult path from discovery to commercialization" says CEO, Marty J Duvall.

Financial overview January-March

Net sales amounted to SEK 19.4 M (0.0)
Operating loss amounted to SEK 347.3 M (loss: 296.9)
Loss for the period was SEK 234.7 M (loss: 297.3)
Loss per share, before and after dilution, was SEK 3.45 (loss: 5.37)
Cash and cash equivalents amounted to SEK 372.5 M (617.8) on March 31
Significant events January-March

PEPAXTO was granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma on 26 February
The US commercial launch of PEPAXTO was successfully initiated in mid-March
PEPAXTO was included in the in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) in Oncology in March
The leadership in Europe was in the beginning of March strengthened with two new significant recruitments to build up European commercial organization
Oncopeptides strengthened the balance sheet through a directed share issue of SEK 1,106 M (USD 130 M). The share issue was completed in April
Significant events after the reporting period

PEPAXTO April net sales amounted to SEK 28.0 M (USD 3.3 M)
An application for conditional marketing authorization of melflufen in the EU submitted in mid- April
Patient enrollment in the phase 2 PORT study was completed in May
Top-line results from the phase 3 OCEAN study was announced on May 25
New dates for publication of the interim reports for Q2 and Q3 2021

Conference call for investors, analysts and the media

Investors, financial analysts and media are invited to participate in a webcast with a Q&A session at 12:00 CEST. The event will be hosted by CEO, Marty J Duvall, CMO, Klaas Bakker and CFO, Anders Martin-Löf.

The webcast will be streamed via this ink which can also be found on the website: www.oncopeptides.com.